Cytovant is a biopharmaceutical company focused on developing novel and innovative cellular therapeutics in Asia. Founded in 2019, Cytovant is backed by investors that include BNH, Mirae Asset Venture Investment, POSCO Venture Capital, and Smilegate Investment and is headquartered in Shanghai.